Hemoglobin biosynthesis denotes the coordinated cellular process by which erythroid precursor cells assemble the tetrameric oxygen-transport protein hemoglobin from its two constituent parts: the prosthetic group heme and the globin polypeptide chains. The process is defined by the convergence of two biosynthetic streams that must be stoichiometrically balanced to avoid the accumulation of unliganded, toxic intermediates ^[1]. Heme is synthesized de novo through an eight-enzyme pathway that, in developing erythroid cells, must support an enormous demand for the prosthetic group; this pathway spans the mitochondrial matrix and the cytoplasm, beginning with the condensation of glycine and succinyl-CoA by 5-aminolevulinate synthase (ALAS) and concluding with the insertion of ferrous iron into protoporphyrin IX by ferrochelatase ^[2]. In parallel, the globin chains are synthesized on cytoplasmic ribosomes under the control of the erythroid transcriptional program, with the specific globin genes expressed—embryonic, fetal, or adult α- and β-type—depending on the developmental stage of the erythroid cell ^[3]. The defining feature of hemoglobin biosynthesis is the assembly phase, in which heme becomes associated with globin chains; this association has been proposed to occur co-translationally, with heme binding to the nascent α-globin chain as it emerges from the ribosome ^[4], and is facilitated by chaperone proteins such as alpha-hemoglobin stabilizing protein (AHSP) that maintain the globin chain in a soluble, assembly-competent state. The term encompasses the entire trajectory—from the enzymatic synthesis of heme and the regulated translation of globin mRNAs through the chaperone-assisted folding and tetramer assembly of the α₂β₂ hemoglobin molecule—as an integrated biosynthetic pathway unique to the erythroid lineage ^[5][6].